Overview
Neuren Pharmaceuticals combines a commercial treatment for Rett syndrome with a pipeline of therapies aimed at several rare neurological disorders. The company’s A$2.6B market capitalisation, A$69.5M in trailing revenue and 17.30% revenue growth frame a business with commercial activity as well as clinical-stage potential. Its 29.14% profit margin is a notable feature, but the shares’ valuation and prospects remain closely tied to product uptake and the uncertain path of drug development.
Neuren Pharmaceuticals is an Australian biotechnology company focused on treatments for neurological disorders. It develops and commercialises DAYBUE (trofinetide) for Rett syndrome, while also advancing clinical-stage programmes including NNZ-2591 for Phelan-McDermid, Angelman and Pitt Hopkins syndromes. This mix of a commercialised treatment and a broader clinical pipeline gives the business potential sources of future growth, but also leaves outcomes dependent on product uptake and drug-development progress.
Key facts
- Ticker
- NEU
- Exchange
- AU
- ISIN
- NZNEUE0001S8
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Currency
- AUD
- Price
- A$20.20
- Previous close
- A$20.26
- Day change
- -A$0.06 (-0.30%)
- Market cap
- 2.6B
- 52W low
- A$10.92
- 52W high
- A$23.59
Price and trend
Last price: A$20.20
- Price
- A$20.20
- 52W range
- A$10.92 – A$23.59
- 50-day SMA
- A$20.99
- 200-day SMA
- A$15.98
- Price vs 50D SMA
- -3.77%
- Price vs 200D SMA
- 26.43%
Valuation
- P/E
- 134.67
- PEG
- 0.00
- EPS
- 0.15
- Dividend yield
- 0.74%
- Beta
- 1.57
Neuren’s market capitalisation is A$2.6B against trailing revenue of A$69.5M, while its P/E ratio is 134.2. That valuation places considerable weight on future earnings and the commercial potential of its neurological treatments. Revenue growth of 17.30% and a profit margin of 29.14% provide evidence of current business momentum and profitability, but investors still need to weigh these figures against the uncertainty of a biotechnology pipeline. The reported dividend yield is 0.74%, a modest component of the overall investment profile.
Profitability and growth
- Revenue growth
- 17.30%
- Revenue TTM
- 69.5M
- Profit margin
- 29.14%
Analyst view
Comparison uses the last price shown; targets are analyst estimates.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
- Price
- A$20.20
- Target price
- A$26.03
- Target vs last price
- 28.86% from last price
The supplied target price is A$26.03, which is 29.31% above the last price. This is a secondary reference point rather than a forecast; the company’s clinical progress, commercial execution and financial results remain central to its prospects.
Risks
Neuren operates in biotechnology, where clinical outcomes, regulatory decisions and commercial uptake can be difficult to predict. Its value depends on developing and commercialising treatments across a relatively focused portfolio, so delays, unsuccessful trials or weaker-than-expected demand could weigh on performance. The shares also show elevated market sensitivity, with a beta of 1.567. At A$20.13, they are below the A$20.88 50-day moving average but above the A$15.96 200-day average, and remain within a wide 52-week range of A$10.92 to A$23.59.
FAQ
What does Neuren Pharmaceuticals do?
Neuren develops treatments for neurological disorders. Its portfolio includes DAYBUE for Rett syndrome and NNZ-2591, which is being studied for several rare neurological conditions.
How large is Neuren Pharmaceuticals?
Neuren has a market capitalisation of A$2.6B and reported trailing revenue of A$69.5M.
Does Neuren pay a dividend?
The supplied figures show a dividend yield of 0.74% and a dividend per share of A$0.15. These figures describe the reported dividend profile and do not guarantee future payments.
What are the main risks for Neuren Pharmaceuticals?
Key risks include the clinical and regulatory uncertainty inherent in drug development, the challenge of commercialising treatments, and the possibility that revenue could be affected by product uptake or reliance on a relatively focused portfolio.
*This content is aimed to provide general information only, and does not take your personal objectives, financial situation or needs into account.
